Fluocinolone Acetonide Intravitreal Implants Application Scope

Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) and diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Fluocinolone Acetonide Intravitreal Implants Characteristics

Ingredients: Active ingredient: Fluocinolone acetonide.
Properties: Fluocinolone acetonide is a synthetic corticosteroid with anti-inflammatory properties.
Packaging Specification: Available as a non-bioerodible intravitreal implant containing 0.19 mg fluocinolone acetonide.
Storage: Store at 15°C to 30°C (59°F to 86°F).
Expiry Date: Not specified; refer to the product packaging for the specific expiry date.
Executive Standard: Complies with the United States Pharmacopeia (USP) standards.
Approval Number: NDA 201923.
Date of Revision: December 2021.
Manufacturer: Alimera Sciences, Inc.

Guidelines for the Use of Fluocinolone Acetonide Intravitreal Implants

Dosage and Administration: Administered as a single intravitreal injection under aseptic conditions.
- Recommended Dose: One implant containing 0.19 mg fluocinolone acetonide.
- Administration: Implant is injected directly into the vitreous cavity using a preloaded applicator.
- Missed Dose: If a dose is missed, administer as soon as possible.
Adverse Reactions:
- Common Adverse Reactions: Increased intraocular pressure, cataract formation, eye pain, and blurred vision.
- Serious Adverse Reactions: Endophthalmitis, retinal detachment, and vitreous hemorrhage
Contraindications:
- Active ocular or periocular infections.
- Hypersensitivity to fluocinolone acetonide or any component of the implant.
Precautions:
- Monitor intraocular pressure regularly during treatment.
- Use with caution in patients with a history of glaucoma.
- Sterility must be maintained during administration to prevent infection.

Fluocinolone Acetonide Intravitreal Implants Interactions

No significant drug interactions have been reported.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.